Read the latest press releases from 10xBio.
10xBio Announces the Completion of Enrollment In Phase 2b Clinical Trial of Novel Drug For Submental Body Contouring
10xBio, LLC, a biotechnology company that focuses on new uses for existing therapies and technologies, announced today that it has completed enrollment in a repeat treatment study of its novel injectable drug for submental body contouring.
10xBio Provides Update on Patent Portfolio
SAN DIEGO (July 15, 2023) – 10xBio, LLC, a privately-held biotechnology company, announces that in the past 24 months it has been issued 3 patents from the U.S. Patent…
10xBio Completes Series B Financing
SAN DIEGO (August 23, 2021) – 10xBio, LLC, a privately-held biotechnology company, completed a Series B financing from a select group of partners and private investors.
Hugel Acquires Phase 2 U.S. Clinical Data to 10XB101 and Exercises China Option for the Drug Product
SAN DIEGO (August 12, 2021) – 10xBio, LLC, a privately-held biotechnology company, announces that its Korean Partner, Hugel…
10xBio Announces the Completion of Phase 2 Clinical Trial of 10XB101
SAN DIEGO (August 3, 2021) – 10xBio, LLC, a privately-held biotechnology company, announced today that it has completed a Phase 2 dose escalation study of its novel injectable drug product for body contouring.
10xBio Announces the Completion of Phase 1B Clinical Trial of 10XB101
SAN DIEGO (May 6, 2019) – 10xBio, LLC, a privately-held biotechnology company, announced today that it has completed a Phase 1B study of its novel injectable drug product for body contouring.
10xBio Announces the Acceptance of a U.S. IND for the Initiation of Clinical Trials of 10XB101
SAN DIEGO (April 2, 2018) – 10xBio, LLC, a privately-held biotechnology company, announced today that the Investigational New Drug “IND” application for 10XB101 has been accepted by the U.S. FDA.
10xBio Completes Series A Financing
SAN DIEGO (April 2, 2018) – 10xBio, LLC, a privately-held biotechnology company, completed a Series A financing from a select group of partners and private investors during the first quarter of 2018.
10xBio Announces Issuance of U.S. Patent
SAN DIEGO (May 31, 2017) – 10xBio, LLC, a privately-held biotechnology company, announced today that it has been issued patent 9,351,945 from the U.S. Patent and Trademark Office.